MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS

被引：0
作者：
Fang, Andrew
Shumaker, Luke
Martin, Kimberly
Onah, Okechukwu
Jackson, Jamaal
Khajir, Ghazal
Fan, Richard
Soodana-Prakash, Nachiketh
Patel, Hiten
Vourganti, Srinivas
Filson, Christopher
Sprenkle, Preston
Sonn, Geoffrey
Punnen, Sanoj
Gupta, Gopal
Rais-Bahrami, Soroush
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD57-01
引用
收藏
页码：E959 / E959
页数：1
相关论文
共 50 条
  • [41] The use of 68Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk
    Yang, Jinhui
    Tang, Yongxiang
    Zhou, Chuanchi
    Zhou, Ming
    Li, Jian
    Hu, Shuo
    PROSTATE, 2023, 83 (05) : 430 - 439
  • [42] Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI
    Jensen, Laura J.
    Kim, Damon
    Elgeti, Thomas
    Steffen, Ingo G.
    Schaafs, Lars-Arne
    Haas, Matthias
    Kurz, Lukas J.
    Hamm, Bernd
    Nagel, Sebastian N.
    CURRENT ONCOLOGY, 2024, 31 (11) : 6814 - 6828
  • [43] Peri-lesional biopsies increase significant prostate cancer detection in men with PI-RADS 4/5 lesions; validation of the PI-RADS steering committee recommendation
    Doan, Paul
    Kim, Lawrence
    Patel, Manish
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 62 - 63
  • [44] PI-RADS 3 Lesions: Role of Prostate MRI Texture Analysis in the Identification of Prostate Cancer
    Giambelluca, Dario
    Cannella, Roberto
    Vernuccio, Federica
    Comelli, Albert
    Pavone, Alice
    Salvaggio, Leonardo
    Galia, Massimo
    Midiri, Massimo
    Lagalla, Roberto
    Salvaggio, Giuseppe
    CURRENT PROBLEMS IN DIAGNOSTIC RADIOLOGY, 2021, 50 (02) : 175 - 185
  • [45] Editorial for "MRI Radiomics-Based Machine Learning for Predict of Clinically Significant Prostate Cancer in Equivocal PI-RADS 3 Lesions"
    Nketiah, Gabriel A.
    Bathen, Tone F.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2021, 54 (05) : 1474 - 1475
  • [46] Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis
    Wadera, Akshay
    Alabousi, Mostafa
    Pozdnyakov, Alex
    Al-Ghita, Mohammed Kashif
    Jafri, Ali
    McInnes, Matthew D. F.
    Schieda, Nicola
    van der Pol, Christian B.
    Salameh, Jean-Paul
    Samoilov, Lucy
    Gusenbauer, Kaela
    Alabousi, Abdullah
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1118)
  • [47] Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
    Lee, Chung-Un
    Lee, Sang-Min
    Chung, Jae-Hoon
    Kang, Minyong
    Sung, Hyun-Hwan
    Jeon, Hwang-Gyun
    Jeong, Byong-Chang
    Seo, Seong-Il
    Jeon, Seong-Soo
    Lee, Hyun-Moo
    Song, Wan
    CANCERS, 2022, 14 (17)
  • [48] Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
    Gomez-Gomez, Enrique
    Moreno Sorribas, Sara
    Valero-Rosa, Jose
    Blanca, Ana
    Mesa, Juan
    Salguero, Joseba
    Carrasco-Valiente, Julia
    Lopez-Ruiz, Daniel
    Jose Anglada-Curado, Francisco
    DIAGNOSTICS, 2021, 11 (08)
  • [49] Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging
    Liang, Zhen
    Feng, Tianrui
    Zhou, Yi
    Yang, Yongjiao
    Sun, Yujiao
    Zhou, Zhien
    Yan, Weigang
    Cao, Fenghong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (01):
  • [50] PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?
    Rico, Luis
    Blas, Leandro
    Vitagliano, Gonzalo
    Contreras, Pablo
    Pita, Hernando Rios
    Ameri, Carlos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (07) : 431.e9 - 431.e13
12345